Juan Jose Maya Villamizar, MD
Rheumatology · Lake Worth, FLNPI 1144660291
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,828 of the $37,348 with a category attached, or 71.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2023 at $11,954 and has fallen 65.7% since, to $4,101 in 2025.
Across 1,463 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kiniksa Pharmaceuticals, Ltd.$7K
- Amgen$5K
- AbbVie$4K
- Kiniksa Pharmaceuticals International, PLC$4K
- Novartis$3K
- AstraZeneca$2K
- plus $13K from 29 others
Across 98 payments — averaging $5339.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$407K
- Novartis$30K
- Daiichi Sankyo Inc.$21K
- Daiichi Sankyo Company LTD$18K
- Astrazeneca UK Limited$16K
- AbbVie$15K
- plus $17K from 2 others
What the payments were for
- Speaking & faculty fees$7,76321%
- Travel & lodging$2,3736%
- Food & beverage$26,82872%
- Education$3851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | 17 | $6,552 |
| Amgen(2 entities) | 412 | $5,356 |
| AbbVie | 175 | $4,089 |
| Kiniksa Pharmaceuticals International, PLC | 12 | $4,032 |
| Novartis | 135 | $2,804 |
| AstraZeneca | 79 | $1,960 |
| Johnson & Johnson(2 entities) | 75 | $1,914 |
| Mallinckrodt Hospital Products Inc. | 84 | $1,819 |
| UCB, Inc. | 105 | $1,748 |
| Pfizer | 113 | $1,692 |
| GSK | 45 | $1,045 |
| Lilly USA, LLC | 43 | $769 |
| Radius Health, Inc. | 35 | $703 |
| Boehringer Ingelheim | 22 | $492 |
| Aurinia Pharma U.S., Inc. | 22 | $435 |
| E.r. Squibb & Sons, L.L.C. | 15 | $313 |
| Janssen Scientific Affairs, LLC | 2 | $269 |
| Octapharma USA, Inc. | 11 | $239 |
| Sobi, Inc | 13 | $218 |
| ANI Pharmaceuticals, Inc. | 7 | $181 |
| Sanofi | 6 | $144 |
| Fresenius Kabi USA, LLC | 4 | $80 |
| Mallinckrodt Enterprises LLC | 4 | $78 |
| Bio Products Laboratory USA, Inc. | 8 | $75 |
| Organon | 5 | $71 |
| Merck | 4 | $61 |
| Genentech USA, Inc. | 2 | $39 |
| Biocon Biologics Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Fortovia Therapeutics, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Seagen Inc. | 1 | $19 |
| Biogen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,348 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 117 | $968,182 |
| RinvoqUpadacitinib | 127 | $876,076 |
| Humira(Cf) PenAdalimumab | 90 | $707,509 |
| Skyrizi PenRisankizumab-Rzaa | 19 | $398,055 |
| ProliaDenosumab | 195 | $339,482 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 44 | $331,329 |
| KevzaraSarilumab | 53 | $230,613 |
| Cimzia (2 Pack)Certolizumab Pegol | 37 | $219,566 |
| OtezlaApremilast | 31 | $149,152 |
| Actemra ActpenTocilizumab | 24 | $114,718 |
| TymlosAbaloparatide | 39 | $113,489 |
| EnbrelEtanercept | 13 | $98,932 |
| Humira(Cf)Adalimumab | 14 | $90,095 |
| Taltz AutoinjectorIxekizumab | 12 | $81,560 |
| HumiraAdalimumab | 12 | $76,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Humira | $4,089 | $1,043,141153 claims |
| AmgenProlia, Otezla, Enbrel | $5,356 | $587,566239 claims |
| SanofiKevzara | $144 | $230,61353 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,748 | $219,56637 claims |
| Radius Health, Inc.Tymlos | $703 | $113,48939 claims |
| Lilly USA, LLCOlumiant | $769 | $35,89913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Lake Worth
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.